Li Li

Dr. Li Li

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TLTao Li
Tao Li
LLLing Liu
Ling Liu
LLLi Li
Li Li
XYXiaoxuan Yao
Xiaoxuan Yao
XHXiaoyuan Hu
Xiaoyuan Hu
HYHong Yao
Hong Yao
The combination of anti-angiogenesis agents with immune-checkpoint inhibitors is a promising treatment for patients with advanced hepatocellular carcinoma (HCC); however, therapeutic resistance caused by cancer stem cells present in tumor microenvironments remains to be overcome. In this study, we report for the first time that the Kringle 1 domain of human hepatocyte growth-factor α chain (HGFK1), a previously described anti-angiogenesis peptide, repressed the sub-population of CD90+ cancer stem cells (CSCs) and promoted their differentiation and chemotherapy sensitivity mainly through downregulation of pre-Met protein expression and inhibition of Wnt/β-catenin and Notch pathways. Furthermore, we showed that the i.p. injection of PH1 (a tumor-targeted and biodegradable co-polymer), medicated plasmids encoding Endostatin (pEndo), HGFK1 genes (pEndo), and a combination of 50% pEndo + 50% pHGFK1 all significantly suppressed tumor growth and prolonged the survival of the HCC-bearing mice. Importantly, the combined treatment produced a potent synergistic effect, with 25% of the mice showing the complete clearance of the tumor via a reduction in the microvessel density (MVD) and the number of CD90+ CSCs in the tumor tissues. These results suggest for the first time that HGFK1 inhibits the CSCs of HCC. Furthermore, the combination of two broad-spectrum anti-angiogenic factors, Endo and HGFK1, is the optimal strategy for the development of effective anti-HCC drugs.

1 January 2025 in Oncology Research
Verified
Journal Article
Open access
PDF file
FLFangyuan Li
Fangyuan Li
XHXiaoyuan Hu
Xiaoyuan Hu
XGXiaoge Gao
Xiaoge Gao
LLLing Liu
Ling Liu
TLTao Li
Tao Li
HYHong Yao
Hong Yao
Background: Liver cancer stem cells (LCSCs) are recognized as pivotal drivers of hepatocellular carcinoma (HCC) progression; however, the molecular mechanisms maintaining their stem-like phenotype remain largely unresolved. This work investigates the role of prefoldin subunit 6-like protein (PFDN6L) in shaping LCSC traits and promoting or restraining HCC progression. Methods: PFDN6L, a cytoskeleton-associated chaperone, was studied using multiple in vitro assays—cell growth evaluation, cell cycle profiling, and spheroid culture—alongside analyses of stemness-associated markers (SOX2, CD133, CD44). Tumorigenic capacity was assessed in xenograft mouse models, and signaling pathway interrogation was performed to define underlying mechanisms. Results: In patient samples, higher PFDN6L expression correlated with improved survival outcomes. Forced expression of PFDN6L induced G2/M arrest, diminished sphere formation, and reduced pluripotency marker expression, whereas knockdown accelerated in vivo tumor formation. Mechanistic experiments demonstrated that PFDN6L suppresses malignancy by simultaneously dampening AKT and ERK1/2 activation, thereby impairing oncogenic signaling cascades. Conclusion: PFDN6L acts as a negative regulator of LCSC-driven tumorigenesis. Its dual blockade of AKT and ERK pathways forms the mechanistic basis of its tumor-suppressive action, supporting its potential as a prognostic biomarker and therapeutic target in HCC.

20 October 2013
Verified
Journal Article
Open access
LLLi Li
Li Li
DWDianhua Wang
Dianhua Wang
XZXuan Zhang
Xuan Zhang
XSXin Song
Xin Song
XMXiaobiao Ma
Xiaobiao Ma
ZHZaoxiu Hu
Zaoxiu Hu
肺纤维化是肺癌放化疗后的常见病理改变,是阻碍药物转运到肺部的关键因素之一,肽转运载体已经成为合理设计肽和肽类药物的靶标,本研究旨在探讨肽转运载体2(peptide transporter 2, PEPT2)mRNA在肺纤维化大鼠肺组织中的表达。 健康SD大鼠50只,随机分为5组。博莱霉素(bleomycin, BLM)7 d、14 d、28 d组:气管内一次性滴入博莱霉素溶液复制肺纤维化大鼠模型,分别于给药后7 d、14 d和28 d放血处死;生理盐水组滴入等量生理盐水,于14 d放血处死;正常组不做任何处理。各组取肺组织,光镜观察组织病理变化;检测样本羟脯氨酸含量;半定量RT-PCR检测肺组织PEPT2 mRNA表达。 BLM 7 d组大鼠肺组织呈急性炎症性改变,无纤维增生;BLM 14 d组和28 d组大鼠肺组织均有纤维化改变,以28 d组最为明显。BLM 7 d组肺组织羟脯氨酸含量与正常对照组和生理盐水组相比无统计学差异(P > 0.05);14 d组和28 d组大鼠肺组织羟脯氨酸含量均高于正常对照组和生理盐水组(P < 0.05)。各组肺组织PEPT2 mRNA的相对表达量无统计学差异(P > 0.05)。 PEPT2 mRNA在博莱霉素致肺纤维化大鼠肺组织表达水平无明显变化,PEPT2可能是设计肺纤维化的新型肽类药物靶标之一。

17 October 2013 in The Chinese-German Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LLLi Li
Li Li
DWDianhua Wang
Dianhua Wang
XZXuan Zhang
Xuan Zhang
XSXing Song
Xing Song

1 January 2026 in BIOCELL
Verified
Journal Article
Open access
PDF file
XMXiaobiao Ma
Xiaobiao Ma
JLJiamin Liu
Jiamin Liu
DLDan Liu
Dan Liu
YYYongjiang Yao
Yongjiang Yao
LLLi Li
Li Li
Background: Immune checkpoint blockade against programmed death-ligand 1 (PD-L1) benefits only a subset of patients with esophageal squamous cell carcinoma (ESCC). The histone demethylase lysine-specific demethylase 5B (KDM5B) drives tumor growth, yet whether it also modulates anti-tumor immunity in ESCC is unknown. This study examined whether the microRNA-29c-3p (miR-29c-3p)/KDM5B axis influences KYSE150 cell behavior and immune-associated responses in vitro. Methods: We quantified KDM5B expression in ESCC cell lines and analyzed public datasets. KYSE150 cells were subjected to KDM5B knockdown or miR-29c-3p overexpression, followed by Cell Counting Kit-8, colony formation, Matrigel invasion, and wound healing. In direct-contact co-culture, tumor cells were exposed to activated peripheral blood mononuclear cells (PBMCs) together with anti-PD-L1; tumor-cell apoptosis, lactate dehydrogenase release, the CD8+ T-cell fraction, and interferon-γ (IFN-γ) output served as readouts. Direct targeting of KDM5B by miR-29c-3p was tested using a dual-luciferase assay coupled with rescue experiments. Results: Compared with normal esophageal epithelial cells, ESCC cells and tissues contained more KDM5B; in public cohorts, higher KDM5B was associated with poorer survival and reduced CD8+ T-cell infiltration. KDM5B silencing or miR-29c-3p overexpression reduced clonogenic growth (p < 0.001, p < 0.01), proliferative rate (p < 0.001, p < 0.001), Matrigel invasion (p < 0.001, p < 0.001), and wound closure (p < 0.01, p < 0.05), and upregulated PD-L1 (p < 0.001). Upon direct-contact co-culture with PBMCs, adding either KDM5B silencing or miR-29c-3p overexpression to anti-PD-L1 further enhanced tumor-cell apoptosis (p < 0.001, p < 0.001), lactate dehydrogenase release (p < 0.001, p < 0.001), the CD8+ T-cell proportion (p < 0.001, p < 0.001), and IFN-γ secretion (p < 0.001, p < 0.001). Importantly, these enhancements were partially attenuated, rather than completely reversed, when KDM5B was restored. A direct interaction between miR-29c-3p and the KDM5B 3′-untranslated region was demonstrated. Conclusions: Through direct targeting of KDM5B, miR-29c-3p restrains ESCC cell growth and remodels CD8- and IFN-γ-associated immune readouts in vitro. Exploiting the miR-29c-3p/KDM5B axis could help surmount resistance to PD-L1 blockade in ESCC, offering a mechanistic rationale for pairing epigenetic modulation with immunotherapy.

13 May 2026 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
DLDan Liu
Dan Liu
XMXiaobiao Ma
Xiaobiao Ma
CGChunlei Ge
Chunlei Ge
QHQian Huang
Qian Huang
YDYiqing Duan
Yiqing Duan
LLLi Li
Li Li
The outcomes of untreated patients with lung adenocarcinoma with brain metastasis are poor; the usual survival period was around weeks to 3 months